We performed a randomized phase II trial of intravenous temsirolimus @mg weekly versus the combination of weekly temsirolimus with a regimen of megestrol acetate @ mg bid for three weeks alternating with tamoxifen @mg bid for three weeks in women with recurrent or metastatic endometrial carcinoma .